This free white paper from Datamonitor Healthcare explores changes in the market access environment in Poland. An increasingly important European market, the Polish pharmaceutical market has recently undergone many changes. The Reimbursement Act, introduced in 2012, has had a negative impact on the reimbursed market segment in terms of changes in the reference pricing system and price renegotiation. However, the pricing and reimbursement process is now more transparent and predictable, and the introduction of risk-sharing schemes opens up opportunities for market access to high-cost therapies.
Highlights in this white paper include:
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: